Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001818382-22-000161)

Filing Details

Accession Number:: 0001818382-22-000161
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-09-19 16:36:28
Reporting Period:: 2022-09-15

Accepted Time:: 2022-09-19 16:36:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818382	Humacyte Inc.	HUMA	Biological Products, (No Disgnostic Substances) (2836)	851763759

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1878075	E Laura Niklason	2525 East North Carolina Highway 54 Durham NC 27713	President, Ceo And Director	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-09-15	1,522,500	$4.00	18,930,004	No	4	S	Indirect	By Ayabudge LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Ayabudge LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,158,240	Direct
Common Stock	510,161	Indirect	By spouse

Footnotes

This sale was made by an entity controlled by the spouse of Laura Niklason, the Reporting Person. This sale was done as a block trade to an existing investor of Humacyte, Inc. Laura Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Laura Niklason were sold in this transaction.